Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
InfuSystem Holdings, Inc. has postponed the release of its third quarter 2026 financial results to evaluate the accounting treatment of $4.2 million in ERP system implementation costs. The company is determining whether these costs should be capitalized and amortized over three years rather than expensed as incurred. Any resulting adjustment would be non-cash and would not impact the company's revenue or cash balances.
Chegg reported Q3 2026 financial results with total net revenues of $46.5 million, a 40% year-over-year decrease, and a net loss of $4.7 million. The company also announced the resignation of board member Marcela Martin, effective December 10, 2026, and highlighted its strategic shift from a homework help company to an employability platform.
Term
Q3 2026
“Over the last year our focus was rearchitecting our cost structure, accumulating cash, eliminating our debt, and positioning Chegg to return to growth. We are evolving Chegg from a homework help company into an employability company, focused on helping people find internships, assess and develop relevant job skills, and secure full-time employment.”
Dan Rosensweig, Executive Chairman and CEO of Chegg
Upstart Holdings reported Q3 2026 financial results with total revenue of $371 million, up 34% year-over-year, and record contribution profit of $218 million. The company's secured lending products (Auto and Home) reached positive contribution margin a quarter ahead of schedule, though management noted macro pressures on the near-term outlook.
Term
Q3 2026
“Macro comes and goes, but alpha compounds. In Q3, our technology and marketing advances helped drive record Contribution Profit, our secured products reached positive Contribution Margin a quarter ahead of plan, and we supported platform growth with proportionately less equity capital. Macro is putting pressure on our near-term outlook, but the progress we’re making gives me more confidence than ever in Upstart’s long-term potential.”
Keurig Dr Pepper reported third quarter 2026 financial results, featuring a 70.6% increase in net sales to $7.34 billion, largely driven by the acquisition of JDE Peet's. The company delivered a 20.4% increase in GAAP diluted EPS and reaffirmed its full-year 2026 financial guidance as it prepares for a planned business separation.
Term
Q3 2026
“We are pleased with our third quarter results, which featured meaningful net sales and EPS growth, along with healthy free cash flow. Our refreshment beverages portfolio maintained its double-digit sales growth momentum and we drove solid results in coffee, led by strong JDE Peet’s profitability. Notably, we achieved these results while stepping up investment behind our brands and capabilities to position our two future companies for success. As we enter the final stretch of the year, we are on track to deliver our 2026 financial commitments and we remain focused on achieving the remaining milestones to enable our planned separation.”
Vital Farms reported total assets of $570.2 million as of September 27, 2026, with a significant increase in cash and cash equivalents to $84.0 million. Notable strategic shifts include the planned discontinuation of butter products and the decision to halt construction on the Vital Crossroads facility in Indiana by the end of 2026.
Precision BioSciences reported Q3 2026 financial results, highlighting a cash position of $108 million which is expected to fund operations through 2028. The company advanced its clinical pipeline, including dosing the first patient in the Phase 1/2 FUNCTION-DMD study and preparing for a late-breaking oral presentation of PBGENE-HBV data at AASLD's The Liver Meeting.
“We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress executing against that plan. In the third quarter, we continued to advance PBGENE-HBV in the ELIMINATE-B trial for chronic hepatitis B and are very excited about the opportunity to present important clinical data in a late-breaking oral presentation at the upcoming AASLD Liver Meeting on November 8th at 2:15pm MST.”
Michael Amoroso, Chief Executive Officer of Precision BioSciences
“The third quarter also marked an important milestone for Precision BioSciences and more importantly for the children who live with Duchenne muscular dystrophy (DMD). Our team alongside our investigators commenced dosing of the first patient in the FUNCTION-DMD trial.”
Michael Amoroso, Chief Executive Officer of Precision BioSciences
For the three months ended September 30, 2026, Marzetti Co reported net sales of $481.5 million, a decrease from $493.5 million in the prior year period. Net income declined to $29.3 million ($1.07 per diluted share) compared to $47.2 million ($1.71 per diluted share) in 2025, primarily driven by lower gross profit and higher selling, general, and administrative expenses.
Xcel Energy priced an upsized private offering of $2.2 billion in 2.625% convertible senior notes due 2027, with an additional $300 million overallotment option for purchasers. The company intends to use the net proceeds to repay short-term debt, including commercial paper and borrowings under its 364-day delayed draw term loan facility.
Eaton reported record third quarter 2026 results with sales of $8.9 billion, up 28% year-over-year, and record segment margins of 25.3%. The company raised its full-year organic growth guidance to 13-15% and adjusted EPS guidance to $13.70-$13.80, citing broad end-market strength and record backlog levels.
Term
Q3 2026
“Our strong third quarter performance reflects the focus and discipline our teams have demonstrated all year as we expand capacity, strengthen execution and position the business to meet accelerating customer demand.”
Paulo Ruiz, Eaton chief executive officer
“We delivered organic growth and segment margins above the high end of our guidance, driven by strong demand across our markets and continued momentum across our Electrical businesses.”
Broadridge Financial Solutions reported Q1 fiscal 2027 results with recurring revenues growing 11% to $1.08 billion and Adjusted EPS increasing 3% to $1.56. The company reaffirmed its full-year fiscal 2027 guidance, including 6-8% recurring revenue growth and 8-12% Adjusted EPS growth, while noting it repurchased $200 million of its own shares during the quarter.
Term
Q1 2027
“Broadridge is driving digital engagement, scaling agentic AI, and accelerating tokenization while delivering strong financial results. Fiscal first quarter Recurring revenue grew 11% constant currency, including 9% Organic growth, and Closed sales rose 10% to $36 million. Adjusted EPS increased 3% to $1.56.”
Tim Gokey, Broadridge CEO
“With a strong start to the year, we are reaffirming our fiscal year 2027 guidance, including 6-8% Recurring revenue growth constant currency, 8-12% Adjusted EPS growth, Free cash flow conversion of 100%+, and strong Closed sales of $290-$330 million.”
Sysco reported first quarter fiscal 2027 results with sales increasing 2.8% to $21.7 billion and adjusted EPS rising 3.5% to $1.19. The company also announced the permanent appointment of Brandon E. Sewell as Executive Vice President and Chief Financial Officer, effective November 1, 2026.
“We are pleased to report a strong start to fiscal 2027. Our Q1 adjusted EPS performance was in-line with our expectations, fueled by positive volume growth, expanding gross margins, and disciplined expense control. We delivered profitable growth across the US and International segments despite continued softness in restaurant foot traffic, higher than expected fuel costs, and lower than expected U.S. food cost inflation.”
Kevin Hourican, Sysco’s Chair of the Board and Chief Executive Officer
“Our teams delivered 2.7% local growth in our U.S. segment and grew adjusted operating income across our USFS and International segments. Our company specific initiatives kept us focused on the elements of performance within our control within a choppy operating environment. Looking ahead, we remain confident in our net cost savings targets enabled by AI technology which include our expectation for $100 million in savings included in our FY27 guidance, with benefits accelerating in the second half.”
Dynatrace reported total revenue of $579.9 million for the quarter ended September 30, 2026, representing a 17% increase year-over-year. Net income before taxes grew to $107.0 million, while the company significantly strengthened its cash position to $2.08 billion following the issuance of $1.41 billion in exchangeable notes.
The Marzetti Company reported fiscal first quarter 2027 results, with net sales declining 2.4% to $481.5 million, significantly impacted by a cyclospora outbreak that reduced demand for dressing and dip products. Net income fell to $1.07 per diluted share from $1.71 in the prior year, driven by lower production volumes, higher freight costs, and commissioning costs for new capacity in Atlanta.
Term
Q1 2027
“The cyclospora outbreak had a significant impact on this quarter’s top and bottom-line results. The outbreak resulted in lower sales for both our Retail and Foodservice segments, with the impact on Retail segment net sales more notable, accounting for an estimated year-over-year net sales decline of approximately 4% due to lower demand for our Retail dressing, dip and crouton products.”
Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, a 29% sequential increase driven by the strong U.S. launch of IMCIVREE for acquired hypothalamic obesity. The company also secured a five-year term loan facility for up to $750 million and announced plans to advance bivamelagon into pivotal development for Prader-Willi syndrome.
Term
Q3 2026
“Rhythm continues to make strong progress in bringing IMCIVREE® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
“We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
Zeo ScientifiX announced that its manufacturing facility is the first to achieve Quality Management Systems (QMS) Certification under a newly established program by the Association for the Advancement of Blood & Biotherapies (AABB). This certification serves as an independent validation of the company's manufacturing quality and operational discipline in the regenerative medicine sector.
Counterparty
Association for the Advancement of Blood & Biotherapies
Nuveen Churchill Direct Lending Corp. reported Q3 2026 net investment income of $0.38 per share and a net asset value of $17.13 per share. The company declared a Q4 distribution of $0.38 per share and highlighted the commencement of operations for its new Senior Loan Fund I joint venture.
Term
Q3 2026
“NCDL reported solid third quarter financial results, highlighting the overall strength and stability of our investment portfolio. Our credit metrics and fundamentals remain strong, reflecting our conservative underwriting approach, as well as our well-diversified portfolio across position sizing and industry concentrations.”
Ken Kencel, President and Chief Executive Officer
“We took meaningful actions to optimize and strengthen our balance sheet and capital structure in the third quarter, including a refinancing of one of our CLOs and the addition of $100 million of unsecured debt.”
Shai Vichness, Chief Financial Officer and Treasurer
Faeth Therapeutics reported a significant net loss of $206.6 million for the nine months ended September 30, 2026, primarily driven by a $133.0 million charge for acquired in-process research and development. The company significantly strengthened its balance sheet during the period, ending with $174.8 million in cash and marketable securities following a private placement and acquisition.
XPLR Infrastructure reported Q3 2026 net income of $51 million and adjusted EBITDA of $471 million. The company updated its 2026 outlook toward the lower end of previous ranges and introduced 2027 guidance, while noting the completion of 85% of its 2026 repowering projects.
Term
Q3 2026
“We delivered solid financial results in the third quarter while continuing to make progress across our key priorities. We have now completed approximately 85% of our planned 2026 repowerings. We also completed sales of approximately 400 megawatts of additional interconnection assets and rights to NextEra Energy Resources, demonstrating the optionality embedded within our portfolio and our ability to unlock incremental value and redeploy capital across the portfolio.”
Alan Liu, president and chief executive officer of XPLR Infrastructure
“In addition, we retired the remaining balance of our 2026 unsecured notes. Today, with greater clarity on our full-year outlook as we approach year-end, we are providing an updated view of our 2026 financial outlook within our existing guidance ranges. In addition, we are introducing our 2027 financial expectations. We believe the underlying characteristics of the business support a durable profile over the longer term, with 2028 FCFBG expected to be in line with 2027.”
Alan Liu, president and chief executive officer of XPLR Infrastructure
Arvinas reported third quarter 2026 financial results and provided a corporate update on its protein degrader pipeline, including the initiation of a Phase 1/2 trial for its HPK1 degrader ARV-6723. The company ended the quarter with $1.1 billion in cash and equivalents, which it expects will fund operations into 2028. Key upcoming milestones include Phase 1 data readouts for ARV-393, ARV-027, and ARV-6723 through 2027.
“We executed strongly during the quarter and are entering an important period of clinical milestones that we believe will demonstrate the promise of our clinical-stage protein degraders. We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients. The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape, and we are grateful to the patients, investigators, and employees whose commitment makes this progress possible.”
Randy Teel, Ph.D., President and Chief Executive Officer of Arvinas
Alkermes plc reported third quarter 2026 total revenues of $480.1 million, driven by solid performance in its proprietary product portfolio including VIVITROL and LUMRYZ. The company reported GAAP net income of $16.3 million and reaffirmed its full-year 2026 financial expectations while highlighting progress in its orexin development programs.
Term
3 months
“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions.”
Blair Jackson, President and Chief Executive Officer
Columbus McKinnon reported Q2 fiscal 2027 results with net sales growing 107% to $539.3 million, primarily driven by the acquisition of Kito Crosby. Despite a net loss of $25.5 million due to integration expenses, the company increased its full-year guidance for sales, Adjusted EBITDA, and Adjusted EPS.
“Building on record orders and sales in the first quarter, our team delivered strong second quarter performance that exceeded expectations. Sequential revenue growth was supported by sustained strength in the Americas and bolstered by stronger than anticipated demand in both Asia and EMEA.”
David J. Wilson, President and Chief Executive Officer
“Our integration of Kito Crosby is progressing well, supported by agile execution and strong collaboration across the combined organization. With our initial integration priorities firmly underway, we are sharpening our focus on the longer-term initiatives that will unlock the potential of the combined business.”
David J. Wilson, President and Chief Executive Officer
Precision BioSciences is a clinical-stage gene editing company focused on its ARCUS technology. As of October 29, 2026, the company had 27,935,719 shares of common stock outstanding and continues to report significant operating losses with a need for substantial additional funding to support its research and development programs.
Madrigal Pharmaceuticals reported third-quarter 2026 financial results, highlighted by Rezdiffra net sales of $431.3 million and the achievement of its first quarter of profitability. The company also announced that Rezdiffra reached blockbuster status with year-to-date net sales of $1.1 billion and plans to initiate a new Phase 3 outcomes trial, MAESTRO-CSPH, in the first half of 2027.
“Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market.”
Bill Sibold, Chief Executive Officer of Madrigal
“Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH.”
UL Solutions reported third-quarter 2026 revenue of $823 million, representing 5.1% total growth and 7.0% organic growth driven by the Industrial and Consumer segments. Net income rose 10.4% to $117 million, while Adjusted EBITDA margin expanded 90 basis points to a record 28.6%. Based on strong performance, the company raised its full-year organic revenue growth outlook to approximately 6.5%.
Term
Q3 2026
“This quarter’s record revenue and excellent margin expansion reflect our strategic focus and investments aligned to the megatrends including the global energy transition and electrification of everything. We are at the forefront of innovation and work alongside our customers as increasingly digital, interconnected products and supply chains drive demand for our trusted services and software.”
Jennifer Scanlon, President and CEO
“Our third-quarter results reflect continued strong execution across the business. We achieved 7.0% organic revenue growth and expanded our Adjusted EBITDA margin to a record 28.6%, driven by broad-based demand, operating leverage and productivity gains.”
Ryan Robinson, Executive Vice President and Chief Financial Officer
Dynatrace reported Q2 fiscal 2027 results with total revenue growing 17% year-over-year to $580 million and ARR increasing 16% to $2.21 billion. Alongside the earnings, the company announced a new $1 billion share repurchase authorization and scheduled an Investor Day for February 2027.
“Our Q2 results reflect continued top-line growth and strong operational efficiency. As organizations increasingly deploy AI agents into production, the need for enterprise-grade observability and governance has never been greater. By bringing Arize together with the Dynatrace platform, we are extending our end-to-end capabilities across the AI lifecycle, from development through production, giving customers greater control over model reliability, application performance, and business outcomes.”
Rick McConnell, Chief Executive Officer
“Our robust cash generation enables us to fund our strategic growth priorities while returning substantial capital to shareholders. Expanding our share repurchase authorization by $1 billion underscores the strength of our balance sheet, our confidence in our long-term growth trajectory, and our commitment to thoughtful capital allocation.”
Xometry reported record third quarter 2026 results, with total revenue increasing 40% year-over-year to $252 million, driven by 43% growth in its AI-native marketplace. The company achieved a significant milestone by surpassing a $1 billion revenue run rate and reaching positive net income of $1.9 million compared to a loss in the prior year period.
Term
Q3 2026
“Our key growth initiatives drove record results in the third quarter, with marketplace growth of 43% year-over-year, as we surpassed the $1 billion revenue run rate. We further improved our marketplace experience and continue to deepen enterprise engagement, driving record net buyer additions and increasing wallet share in larger accounts.”
Sanjeev Singh Sahni, CEO at Xometry
“Our record-setting Q3 performance demonstrates the compounding growth and operational efficiency of our marketplace, delivering both strong revenue expansion and margin improvement. Revenue growth remained robust at the 40% level for the second quarter in a row, alongside record marketplace gross margin of 36.0%.”
Versant Media Group reported Q3 2026 revenue of $1.59 billion and net income of $47 million, driven by double-digit Platforms revenue growth and strong network viewership. The company reaffirmed its full-year outlook and raised its Free Cash Flow forecast to exceed $1.2 billion while announcing an additional $100 million accelerated share repurchase program.
Term
Q3 2026
“Versant’s momentum continues, with audience growth and the completion of all planned pay television distribution renewals for the year, underscoring the value and enduring appeal of our brands.”
Mark Lazarus, Chief Executive Officer
“Our third quarter performance demonstrates the financial discipline and flexibility that underpins Versant’s strategy. We delivered strong Platforms revenue, continued operating efficiencies and significant cash flow.”
Anand Kini, Chief Financial Officer and Chief Operating Officer
Driven Brands announced that its financial statements for fiscal years 2023, 2024, and 2025, as well as the first two quarters of 2026, can no longer be relied upon due to material errors in fixed asset reporting. The company is undergoing a restatement process primarily related to the failure to timely write-off fixed assets and incorrect useful life classifications. Consequently, the company has delayed its Q3 2026 earnings call and Form 10-Q filing.
Anavex Life Sciences Corp. has appointed Terrie Kellmeyer, Ph.D., as its permanent President and Chief Executive Officer and as a member of the Board of Directors, effective November 1, 2026. Dr. Kellmeyer, who had been serving as Interim CEO since May 2026, will maintain an annual base salary of $500,000 with an anticipated 30% bonus. The appointment follows her leadership during a period of clinical program focus and increased engagement with the FDA.
Shopify reported Q3 2026 financial results with revenue increasing 32% year-over-year to $3.74 billion and GMV reaching $119.1 billion. The company achieved a free cash flow margin of 22% and expects Q4 revenue to continue growing at a low-thirties percentage rate.
Term
Q3 2026
“Shopify is uncommonly good at operating in two realities at the same time: the world our merchants exist in today, and the one they are moving towards. Q3 is the perfect example. We powered $119 billion in GMV, while continuing to build commerce into every surface, every agent, and increasingly, everywhere.”
Harley Finkelstein, President of Shopify
“Delivering these results at our scale speaks to the strength of our model, our multiple growth drivers, and our expanding addressable market.”
Jeff Hoffmeister, Chief Financial Officer of Shopify